このエントリーをはてなブックマークに追加
ID 45927
本文ファイル
著者
Shimada, Hiroyuki
Kada, Akiko
Shima, Haruko
Tono, Chikako
Yuza, Yuki
Kurosawa, Hidemitsu
Watanabe, Akihiro
Ito, Masaki
Uryu, Hideko
Kamibeppu, Kiyoko
Kiyokawa, Nobutaka
Adachi, Souichi
Saito, Akiko M.
Tanizawa, Akihiko
キーワード
chronic myeloid leukaemia
children
tyrosine kinase inhibitors
NDC
医学
抄録(英)
Chronic myeloid leukaemia (CML) is a relatively rare disease in children, accounting for 2–3% of all paediatric leukaemia cases. Generally, children with CML can avoid hematopoietic stem cell transplantation and achieve molecular responses with tyrosine kinase inhibitors (TKI). However, CML stem cells are thought to survive in many patients, even after TKI treatment. Many aspects of the toxic effects of prolonged exposure to TKIs during childhood remain unclear, particularly those regarding growth impairment. This lack of clarity underscores the importance of the present clinical trial, which aims to clarify the feasibility of treatment-free remission (TFR) in children following TKI treatment. We aim to examine the long-term out-comes and complications of TKIs before and after cessation to better understand the unknown complications that could arise in adulthood. This trial targets patients who were diagnosed with CML at an age younger than 20 years, were in the chronic or accelerated phase at initial diagnosis and remained in complete molecular remission for at least 2 years after TKI administration. We will examine the utility of TKI cessation and assess the treatment results of patients who resumed TKI therapy after losing a major molecular response. We will also investigate factors related to the feasibility of a TFR after TKI cessation.
掲載誌名
Hiroshima Journal of Medical Sciences
67巻
1号
開始ページ
7
終了ページ
13
出版年月日
2018-03
出版者
Hiroshima University Medical Press
ISSN
0018-2052
2433-7668
NCID
出版者DOI
言語
英語
NII資源タイプ
紀要論文
広大資料タイプ
学内刊行物(紀要等)
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
publisher
権利情報
Copyright (c) 2018 Hiroshima University Medical Press
関連情報URL
部局名
医歯薬保健学研究科
他の一覧